Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
33,071,782
-
Shares change
-
-2,424,263
-
Total reported value, excl. options
-
$123,053,543
-
Value change
-
-$11,174,770
-
Put/Call ratio
-
225%
-
Number of buys
-
69
-
Number of sells
-
-55
-
Price
-
$3.72
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q2 2022
157 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33,071,782 shares
of 1,079,784,035 outstanding shares and own 3.1% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (7,522,377 shares), BlackRock Inc. (5,907,519 shares), STATE STREET CORP (1,868,524 shares), GEODE CAPITAL MANAGEMENT, LLC (1,572,834 shares), MILLENNIUM MANAGEMENT LLC (1,179,785 shares), JPMORGAN CHASE & CO (1,161,894 shares), MORGAN STANLEY (978,410 shares), CITADEL ADVISORS LLC (777,981 shares), NORTHERN TRUST CORP (754,874 shares), and CREDIT SUISSE AG/ (688,474 shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.